central precocious puberty
Endocrinology · 2014–2022
4decisions
3medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| leuprorelin acetate Treatment of central precocious puberty (CPP) in girls 10 years or younger or boys 11 years or younger. | Jul 2022 | Recommended | none received |
| triptorelin Treatment of central precocious puberty (CPP) in children aged 2 years and older with onset before 8 years in girls and 10 years in boys. | Jul 2021 | Recommended with restriction | unclear |
| leuprorelin Treatment of central precocious puberty (CPP) in children with onset of signs or symptoms prior to age 8 years (girls) or 9 years (boys). | Jul 2015 | Recommended | none received |
| leuprorelin Treatment of central precocious puberty (CPP) in children with progressive disease. | Nov 2014 | Recommended | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.